Crysvita

Active Ingredient(s): Burosumab
FDA Approved: * April 17, 2018
Pharm Company: * ULTRAGENYX PHARM INC
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Crysvita Overview

Burosumab (INN, trade name Crysvita) known as KRN23 is a human monoclonal antibody designed for the treatment of X-linked hypophosphatemia.[1][2][3] Burosumab was approved by the FDA for its intended purpose, in patients aged 1 year and older, on 17 April 2018.[4] The FDA approval fell under both the breakthrough therapy and orphan drug designations.[4] This drug was developed by Ultragenyx and is in a collaborative license agreement with Kyowa Hakko Kirin.[5] References ^ Statement On A ...

Read more Crysvita Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Burosumab

Recent Crysvita Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Burosumab

Injection: 10mg/ml

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Crysvita: (3 results)

Sorted by National Drug Code

69794-102 Crysvita 10 mg/ml Subcutaneous Injection by Ultragenyx Pharmaceutical Inc.
69794-203 Crysvita 20 mg/ml Subcutaneous Injection by Ultragenyx Pharmaceutical Inc.
69794-304 Crysvita 30 mg/ml Subcutaneous Injection by Ultragenyx Pharmaceutical Inc.

Other drugs which contain Burosumab or a similar ingredient: (1 result)

Burosumab